Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~For children group (aged from 12-36 months):~* Healthy children aged from 12 to 36 months old as established by medical history and clinical examination~* The subjects' guardians are able to understand and sign the informed consent~* Had never received the vaccine against EV71~* Subjects who can and will comply with the requirements of the protocol~* Subjects with temperature \<=37.0°C on axillary setting~For infants group (aged from 6-11 months):~* Healthy infants aged from 6 to 11 months old as established by medical history and clinical examination~* The subjects' guardians are able to understand and sign the informed consent~* Had never received the vaccine against EV71~* Subjects who can and will comply with the requirements of the protocol~* Subjects with temperature \<=37.0°C on axillary setting~Exclusion Criteria:~For children group (aged from 12-36 months):~* Subject who has a medical history of HFMD~* \<= 37 weeks gestation~* Subjects with a birth weight \<2.5 kg~* Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine~* Family history of seizures or progressive neurological disease~* Family history of congenital or hereditary immunodeficiency~* Severe malnutrition or dysgenopathy~* Major congenital defects or serious chronic illness, including perinatal brain damage~* Autoimmune disease~* Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws~* Any acute infections in last 7 days~* Any prior administration of immunodepressant or corticosteroids in last 6month~* Any prior administration of blood products in last 3 month~* Any prior administration of other research medicines in last 1 month~* Any prior administration of attenuated live vaccine in last 28 days~* Any prior administration of subunit or inactivated vaccines in last 14 days, such as pneumococcal vaccine~* Under the anti-TB prevention or therapy~* Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives~For infants group (aged from 6-11 months):~* Subject who has a medical history of HFMD~* \<= 37 weeks gestation~* Subjects with a birth weight \<2.5 kg~* Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine~* Family history of seizures or progressive neurological disease~* Family history of congenital or hereditary immunodeficiency~* Severe malnutrition or dysgenopathy~* Major congenital defects or serious chronic illness, including perinatal brain damage~* Autoimmune disease~* Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws~* Any acute infections in last 7 days~* Any prior administration of immunodepressant or corticosteroids in last 6month~* Any prior administration of blood products in last 3 month~* Any prior administration of other research medicines in last 1 month~* Any prior administration of attenuated live vaccine in last 28 days~* Any prior administration of subunit or inactivated vaccines in last 14 days, such as pneumococcal vaccine~* Under the anti-TB prevention or therapy~* Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives~Exclusion Criteria for the second dose:~* Had any Grade 3 or Grade 4 adverse reaction within 7 days after first dose~* Any situation meet the exclusion criteria stated in the exclusion criteria for first dose~* Had any SAE related to first dose during the following-up of first dose~* Any condition that in the opinion of the investigator, or IRB

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 36 Months
- Healthy Volunteers: f

Study Arms:
- 160U /0.5ml in children (from 12 to 36 months old) (Type: EXPERIMENTAL): inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 120 children aged 12-36 months old on day0,28
- 320U /0.5ml in children (from 12 to 36 months old) (Type: EXPERIMENTAL): inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 120 children aged 12-36 months old on day0,28
- 640U /0.5ml in children (from 12 to 36 months old) (Type: EXPERIMENTAL): inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 120 children aged 12-36 months old on day0,28
- (without adjuvant) 640U /0.5ml in children (12-36months) (Type: EXPERIMENTAL): inactivated vaccine(vero cell) against EV71 of (without adjuvant) 640U /0.5ml in 120 children aged 12-36 months old on day0,28
- 160U /0.5ml in infants (from 6 to 11 months old) (Type: EXPERIMENTAL): inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 120 infants aged 6-11 months old on day0,28
- 320U /0.5ml in infants (from 6 to 11 months old) (Type: EXPERIMENTAL): inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 120 infants aged 6-11 months old on day0,28
- 640U /0.5ml in infants (from 6 to 11 months old) (Type: EXPERIMENTAL): inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 120 infants aged 6-11 months old on day0,28
- (without adjuvant) 640U /0.5ml in infants (from 6 to 11 months (Type: EXPERIMENTAL): inactivated vaccine(vero cell) against EV71 of (without adjuvant) 640U /0.5ml in 120 infants aged 6-11 months old on day0,28
- 0/0.5ml placebo in children (from 12 to 36 months old) (Type: PLACEBO_COMPARATOR): 0/0.5ml placebo in 120 children aged 12-36 months old on day0,28
- 0/0.5ml placebo in infants (from 6 to 11 months old) (Type: PLACEBO_COMPARATOR): 0/0.5ml placebo in 120 infants aged 6-11 months old on day0,28

Based on this trial design, predict the completion outcome and termination type (if applicable).